Skip to main content

Dermatomyositis clinical trials at UCLA

3 in progress, 1 open to eligible people

Showing trials for
  • Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy.

    open to eligible people ages 18 years and up

    This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome [ASyS]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found on https://myositis-study.com/.

    Los Angeles, California and other locations

  • Brepocitinib in Adults with Dermatomyositis

    Sorry, in progress, not accepting new patients

    This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where all participants will receive brepocitinib.

    Los Angeles, California and other locations

  • IgPro20 in Adults With Dermatomyositis (DM)

    Sorry, in progress, not accepting new patients

    This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.

    Los Angeles, California and other locations

Last updated: